Monoclonal Antibody to CD86
Phycoerythrin (PE) conjugated (100 tests)

Clone: BU63
Isotype: Mouse IgG1
Specificity: The antibody BU63 reacts with CD86 (B7-2), a 70 kDa type I transmembrane glycoprotein of immunoglobulin supergene family, expressed on professional antigen-presenting cells, such as dendritic cells, macrophages or activated B lymphocytes.
HLDA V; WS Code BP BP072
HLDA V; WS Code A A109
HLDA VI; WS Code BP 95
HLDA VI; WS Code B CD86.9

Regulatory Status: RUO
Immunogen: B-lymphoblastoid cell line ARH 77
Species Reactivity: Human, Other not determined
Preparation: The purified antibody is conjugated with R-Phycoerythrin (PE) under optimum conditions. The conjugate is purified by size-exclusion chromatography and adjusted for direct use. No reconstitution is necessary.
Storage Buffer: The reagent is provided in stabilizing phosphate buffered saline (PBS) solution containing 15mM sodium azide.
Storage / Stability: Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not use after expiration date stamped on vial label.
Usage: The reagent is designed for Flow Cytometry analysis of human blood cells using 20 µl reagent / 100 µl of whole blood or 10^6 cells in a suspension. The content of a vial (2 ml) is sufficient for 100 tests.

Expiration: See vial label
Lot Number: See vial label
Background: CD80 (B7-1) and CD86 (B7-2) are ligands of T cell critical costimulatory molecule CD28 and of an inhibitory receptor CTLA-4 (CD152). The both B7 molecules are expressed on professional antigen-presenting cells and are essential for T cell activation, the both molecules can also substitute for each other in this process. The question what are the differences in CD80 and CD86 competency has not been fully elucidated yet; there are still conflicts in results about their respective roles in initiation or sustaining of the T cell immune response.
References:

*Vasilevko V, Ghochikyan A, Holterman MJ, Agadjanyan MG: CD80 (B7-1) and CD86 (B7-2) are functionally equivalent in the initiation and maintenance of CD4+ T-cell proliferation after activation with suboptimal doses of PHA. DNA Cell Biol. 2002 Mar;21(3):137-49.


*And many other.